Sangamo Therapeutics (NASDAQ:SGMO) is a clinical-stage biotechnology company dedicated to developing genomic therapies to treat serious and life-threatening diseases. Leveraging its proprietary zinc finger nuclease (ZFN) platform, Sangamo designs and engineers targeted DNA-binding proteins to enable precise gene editing, gene regulation, and cell engineering. The company’s research focuses on delivering durable, one-time treatments that address the underlying genetic causes of disease rather than managing symptoms.
The company’s pipeline spans multiple therapeutic areas, including rare monogenic disorders, hemophilia, neurometabolic conditions and immuno-oncology. Sangamo’s lead programs utilize in vivo editing to restore or augment deficient genes, as well as ex vivo approaches in which patient cells are modified outside the body and then infused to provide long-lasting therapeutic benefits. Collaboration agreements with pharmaceutical and academic partners support clinical development efforts and help expand Sangamo’s capabilities in manufacturing and regulatory strategy.
Founded in 1995 and headquartered in Brisbane, California, Sangamo maintains research sites across the United States and Europe. Over the years, the company has advanced several first-in-class therapies into clinical trials, attracting investment and collaborations with major industry players. Sangamo’s global footprint allows it to engage with patient communities, investigator networks and regulatory authorities to accelerate development timelines and facilitate commercial readiness.
Under the leadership of an experienced executive management team and a board of directors with deep expertise in biotechnology and genomics, Sangamo continues to refine its platform technologies and expand its pipeline. The company is committed to translating scientific innovation into transformative therapies and remains focused on strategic partnerships, operational excellence and patient-centric development to bring its genomic medicines to those in need.
